Sexually Transmitted Infections (STIs) Market Size and Forecast 2024-2033|Pfizer Inc., Johnson & Johnson, Roche Holdings AG, Merck & Co Inc., AbbVie Inc

Overview and Scope

Sexually transmitted infections (STIs), also known as sexually transmitted diseases (STDs), refer to diseases caused by viruses, bacteria and parasites that are passed from one person to another through sexual contact. These infections can be transmitted by vaginal, anal and oral sex and through skin-to-skin contact.

Sizing and Forecast

The sexually transmitted infections (stis) market size has grown rapidly in recent years. It will grow from $56.17 billion in 2023 to $63.69 billion in 2024 at a compound annual growth rate (CAGR) of 13.4%. The growth in the historic period can be attributed to behavioral factors, education and awareness, healthcare access, antibiotic development.

The sexually transmitted infections (stis) market size is expected to see rapid growth in the next few years. It will grow to $100.66 billion in 2028 at a compound annual growth rate (CAGR) of 12.1%. The growth in the forecast period can be attributed to emerging sti strains, vaccination initiatives, telemedicine and at-home testing, sexual health equity. Major trends in the forecast period include rise of antimicrobial resistance, pre-exposure prophylaxis (prep), sti self-management, enhanced sexual education.

To access more details regarding this report, visit the link:

https://www.thebusinessresearchcompany.com/report/sexually-transmitted-infections-stis-global-market-report

Segmentation & Regional Insights

The sexually transmitted infections (stis) market covered in this report is segmented –

1) By Type: Human Immunodeficiency Virus (HIV); Human Papilloma Virus (HPV); Gonorrhea; Syphilis; Other Types

2) By Treatment: Antibiotics; Antiviral

3) By Location Of Testing: Laboratory Testing; Point-Of-Care (POC) Testing

4) By Route Of Administration: Oral; Parenteral; Other Route Of Administration

5) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users

North America was the largest region in the sexually transmitted infection (STIs) market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in sexually transmitted infections (STIs) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13047&type=smp

Major Driver Impacting Market Growth

The surge in government initiatives for spreading awareness of sexually transmitted infections is expected to propel the growth of the sexually transmitted infections (STIs) market going forward. A government initiative is a program or policy implemented to achieve a specific goal and address particular problems. The government offers several initiatives to prevent, control and treat sexually transmitted infections (STIs), such as funds for public education campaigns to raise awareness of STIs, vaccines to prevent certain STIs and free or low-cost screening and testing. For instance, in April 2023, Springfield-Greene County Health, a US-based public health department, announced Disease Intervention Specialist (DIS), a new program and partnership with the Missouri Department of Health and Senior Services (Missouri DHSS) to combat the rising spread of sexually transmitted infections (STIs) in Greene County. The two experts in the DIS program, who will primarily focus on syphilis and HIV, will contact those who test positive for these illnesses, connect them with options for treatment and help identify and get in touch with them to make them aware of the infection. Therefore, the surge in government initiatives will drive the sexually transmitted infections (STIs) market.

Key Industry Players

Major players in the sexually transmitted infections (stis) market are Pfizer Inc., Johnson & Johnson, Roche Holdings AG, Merck & Co Inc., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb, Astra Zeneca Pharmaceuticals LP, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Hetero Drugs Ltd., Eisai Co. Ltd., Boehringer Ingelheim Group, Sun Pharmaceutical Industries Ltd., Lupin Limited, Dr. Reddy’s Laboratories, Wockhardt Ltd., Zydus Lifescience Ltd., Glenmark Pharmaceuticals Ltd., Cipla Ltd., Torrent Pharmaceuticals Ltd., Otsuka Pharmaceutical Co. Ltd.

The sexually transmitted infections (stis) market report table of contents includes:

1. Executive Summary

2. Sexually Transmitted Infections (STIs) Market Characteristics

3. Sexually Transmitted Infections (STIs) Market Trends And Strategies

4. Sexually Transmitted Infections (STIs) Market – Macro Economic Scenario

5. Global Sexually Transmitted Infections (STIs) Market Size and Growth

26. South America Sexually Transmitted Infections (STIs) Market

27. Brazil Sexually Transmitted Infections (STIs) Market

28. Middle East Sexually Transmitted Infections (STIs) Market

29. Africa Sexually Transmitted Infections (STIs) Market

30. Sexually Transmitted Infections (STIs) Market Competitive Landscape And Company Profiles

Top Major Players: